Skip to content

Financial Reports

Our financial reports are only available in Swedish.


Subscribe to AcuCort's newsletter

* indicates required


Message from the CEO

“AcuCort is entering a new and exciting phase, focusing on the commercialisation of our innovative and patient-friendly oral film Zeqmelit®, for acute and severe allergic reactions, among others.”

Jonas Jönmark, CEO, AcuCort AB
February 24, 2023

We make good drugs better

AcuCort develops innovative treatments based on existing and well-documented substances in treatment areas where there is a high unmet medical need and commercial interest in new drugs that add benefits such as simplicity of administration.

Latest videos from AcuCort

AcuCort at BioStock Life Science Spring Summit 2023

AcuCort AB

June 1, 2023 08:45

AcuCort – Q1 2023

AcuCort AB

May 3, 2023 10:38

Acucort – Stora Aktiedagen Stockholm 15 mars 2023

AcuCort AB

March 16, 2023 09:45

AcuCort – Bokslutskommuniké 2022

AcuCort AB

February 24, 2023 10:48